ArticleFrontiers in oncology2026
Human endogenous retrovirus profiling reveals heterogenous expression in cutaneous melanoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Locus-specific HERV expression identifies an aggressive, NK-depleted, checkpoint-refractory acral melanoma phenotype.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Cutaneous melanoma (CM) is a cancer of the pigment-producing melanocytes of the skin. Advances in treatment with immune checkpoint inhibitors (ICI) have greatly improved the outcomes, although not all patients with CM respond to ICI. Emerging evidence shows that ICI responsiveness is correlated with the expression of certain human endogenous retroviruses (HERVs). We aimed to investigate the relationships between HERV expression and outcomes in patients with CM. Methods: We characterized HERV expression from 330 patients with primary or metastatic CM using Telescope, a computational software package that calculates the expression of HERV loci from bulk RNA sequencing datasets. Results: We found that HERVs expression differed between primary and metastatic CM. Using HERV expression alone, three subtypes of metastatic CM had distinct survival outcomes. Among the differentially expressed HERV loci in metastatic and treatment non-responders, we identified HERV-FRD which has the potential to produce the endogenous retrovirus group V Env polyprotein (syncytin-2) precursor. Conclusion: Our analyses demonstrate the unique features of HERV expression in CM metastases and in ICI responsiveness. These exploratory findings identify modulated HERVs in CM, and further studies should be developed to determine whether HERV expression has any predictive or clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.